Plateletapheresis: instrumentation validation

FDA Memorandum, Docket No. 91N-0450, Guideline for Quality Assurance in Blood Establishments. July 11, 1995 FDA Memorandum, Guideline on General Principals of Process Validation. May, 1987 Standards for Blood Banks and Transfusion Services. Bethesda, MD: American Association of Blood Banks, 18th ed. 1997:67 FDA Memorandum, document #4027, Recommendations and licensure requirements for leukocyte-reduced blood products. May 29, 1996 Dumont, 1996, Practical guidelines for process validation and process control of white cell-reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT), Transfusion, 36, 11, 10.1046/j.1537-2995.1996.36196190510.x McCall M, Dumont L, Adams M. Required sample sizes for detecting small continuous shifts in leukocyte-reduced products. Transfusion 1997;37 (Suppl):78S (Abstract) Operators Manual, Revision 1.4, Fenwal Amicus Separator. Deerfield, IL:Baxter Healthcare Corporation. March 1997:A-12 Standards of Blood Banks and Transfusion Services. Bethesda, MD:American Association of Blood Banks, 18th ed. 1997:16-17 COBE Spectra Apheresis System Operator’s Manual for Use of Version 5.1 Software Program. Lakewood, CO:COBE BCT, Inc, October 1995:4C-10 EZQC™ Training Guide, Version 2.0. Lakewood CO:COBE BCT, Inc, 1997:39 EZQC™ Training Guide, Version 2.0. Lakewood CO:COBE BCT, Inc, 1997:40 EZQC™ Training Guide, Version 2.0. Lakewood CO:COBE BCT, Inc, 1997:5 Moroff, 1991, Concepts about current conditions for the preparation and storage of platelets, Transfusion Medicine Reviews, V, 48, 10.1016/S0887-7963(91)70192-2